Travere Therapeutics, Inc. TVTX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s financing cash flow?
- Travere Therapeutics, Inc. (TVTX) reported financing cash flow of $4.2M in Q1 2026.
- How has Travere Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Travere Therapeutics, Inc.'s financing cash flow increased by 13.1% year-over-year, from $3.72M to $4.2M.
- What is the long-term trend for Travere Therapeutics, Inc.'s financing cash flow?
- Over 3 years (2021 to 2024), Travere Therapeutics, Inc.'s financing cash flow has grown at a -15.6% compound annual growth rate (CAGR), from $231.68M to $139.42M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.